₹1,078.95
▼ -22.47 -2.04%
17 Jul 2026
NSE Listed
ASM 1Orchid Pharma Limited (ORCHPHARMA)
Volume: 3,20,974Avg Vol 1W: 3,67,584.8Avg Vol 1M: 3,29,124.552W Range:₹480₹1,119.8
Key Ratios
Checked 23h agoMarket Cap₹5,586 Cr
Current Price₹1,078.95
Previous Close₹1,101.42
High / Low (52w)₹1,119.8 / ₹480
Volume3,20,974
Avg Vol (1W)3,67,584.8
Avg Vol (1M)3,29,124.5
Stock P/E234.84
Book Value₹253.9
Dividend Yield0%
ROE2.1%
ROA1.1%
Revenue (TTM)₹949 Cr
Revenue Growth12.5%
Profit Margin2.5%
Total Debt₹132 Cr
Shares Outstanding5 Cr
Face Value₹10
EPS (TTM)₹4.69
P/B4.34
Debt / Equity0.28
50 DMA₹896.13
200 DMA₹745.19
Day change-2.04%
SurveillanceASM 1 (as of 2026-07-15)
Price Chart
₹1,078.95▲ 45.54% · 1Y
2025-07-172026-07-15
20-day avg volume: 3.3L shares
Pros
- Company is almost debt-free.
- Revenue grew 14% YoY.
Cons
- Company is loss-making at the latest annual result.
- Stock trades at a high P/E of 235.
Quarterly Results
| Metric | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹244 Cr | ₹223 Cr | ₹217 Cr | ₹237 Cr | ₹173 Cr | ₹194 Cr | ₹207 Cr | ₹238 Cr |
| EBITDA | ₹32 Cr | ₹29 Cr | ₹26 Cr | ₹23 Cr | ₹17 Cr | ₹0 Cr | ₹-2 Cr | ₹25 Cr |
| Net Profit | ₹29 Cr | ₹27 Cr | ₹21 Cr | ₹22 Cr | ₹15 Cr | ₹-6 Cr | ₹-13 Cr | ₹24 Cr |
| EPS | — | — | — | — | — | — | — | — |
Profit & Loss (Annual)
| Metric | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹703 Cr | ₹617 Cr | ₹508 Cr | ₹465 Cr | ₹569 Cr | ₹685 Cr | ₹850 Cr | ₹949 Cr |
| EBITDA | ₹-97 Cr | ₹-131 Cr | ₹-66 Cr | ₹-44 Cr | ₹-25 Cr | ₹48 Cr | ₹108 Cr | ₹110 Cr |
| Net Profit | ₹-353 Cr | ₹69 Cr | ₹-131 Cr | ₹-117 Cr | ₹-2 Cr | ₹46 Cr | ₹92 Cr | ₹100 Cr |
| EPS | -39.65 | 7.8 | -14.75 | -28.55 | -0.48 | 11.35 | 19.06 | 19.65 |
Balance Sheet
| Metric | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | ₹3,125 Cr | ₹3,077 Cr | ₹1,460 Cr | ₹1,237 Cr | ₹1,111 Cr | ₹1,225 Cr | ₹1,554 Cr | ₹1,688 Cr |
| Total Liabilities | ₹3,917 Cr | ₹3,781 Cr | ₹694 Cr | ₹584 Cr | ₹463 Cr | ₹537 Cr | ₹384 Cr | ₹421 Cr |
| Equity | ₹-792 Cr | ₹-704 Cr | ₹766 Cr | ₹653 Cr | ₹647 Cr | ₹689 Cr | ₹1,169 Cr | ₹1,267 Cr |
| Total Debt | — | — | — | — | — | — | — | — |
Cash Flow
| Metric | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating | ₹16 Cr | ₹16 Cr | ₹70 Cr | ₹19 Cr | ₹94 Cr | ₹19 Cr | ₹125 Cr | ₹20 Cr |
| Investing | ₹-28 Cr | ₹45 Cr | ₹167 Cr | ₹67 Cr | ₹113 Cr | ₹-31 Cr | ₹-312 Cr | ₹-27 Cr |
| Financing | ₹33 Cr | ₹0 Cr | ₹-250 Cr | ₹-165 Cr | ₹-217 Cr | ₹31 Cr | ₹167 Cr | ₹25 Cr |
| Free Cash Flow | ₹16 Cr | ₹16 Cr | ₹70 Cr | ₹19 Cr | ₹94 Cr | ₹19 Cr | ₹125 Cr | ₹20 Cr |
Shareholding
Promoter 69.84% Institutions 21.12% Public 9.05%
Efficiency & Working Capital
ROCE2.5%
Interest Coverage7.4
Dividend Payout—
Debtor Days96 d
Inventory Days129 d
Payable Days88 d
Cash Conversion Cycle137 d
Working Capital Days225 d
Shareholding Details
As of 2026-03-31
Promoter69.8%
FII0.9%
DII20.2%
Institutions21.1%
Public9%
Promoter Pledge0%
No. of Shareholders35,118
Shareholding Pattern
Quarterly — figures in %. Latest 12 quarters.
| Period | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 72.4% | 72.4% | 69.8% | 69.8% | 69.8% | 69.8% | 69.8% | 69.8% | 69.8% | 69.8% | 69.8% | 69.8% |
| FIIs | 0.5% | 8.1% | 4.1% | 2% | 1.4% | 1.9% | 2.5% | 2.7% | 1.4% | 1.6% | 1.2% | 0.9% |
| DIIs | 13.5% | 9.9% | 14.5% | 17.7% | 18.9% | 18.3% | 19% | 20.1% | 19.4% | 19% | 19.4% | 20.2% |
| Public | 13.7% | 9.6% | 11.5% | 10.5% | 9.8% | 9.9% | 8.6% | 7.4% | 9.3% | 9.6% | 9.6% | 9% |
| Promoter Pledge | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| No. of Shareholders | 29,132 | 29,197 | 36,931 | 36,720 | 34,695 | 36,363 | 34,158 | 34,303 | 39,827 | 38,155 | 35,709 | 35,118 |
Returns History (ROE / ROCE / ROA)
| Period | ROE | ROCE | ROA | P/E |
|---|---|---|---|---|
| 202503 | — | — | — | — |
Major Shareholders (>1%)
| Name | Category | Stake | Shares |
|---|---|---|---|
| Dhanuka Laboratories Limited | Shareholding of Promoter and Promoter Group | 69.8% | 3.54 Cr |
| Quant Mutual Fund - Quant Small Cap Fund | Public Shareholding | 6.8% | 34,65,947 |
| Kotak Mahindra Trustee Co Ltd A/c Kotak Multi Asset Allocation Fund And 5 Others | Public Shareholding | 4.3% | 21,86,309 |
| Uti-healthcare Fund And 3 Others | Public Shareholding | 3.6% | 18,23,362 |
| Invesco India Equity Savings Fund And 2 Others | Public Shareholding | 2.9% | 14,56,510 |
| Bandhan Bse Healthcare Index Fund And 3 Others | Public Shareholding | 1.4% | 7,10,726 |
Promoter Pledges
| Holder | Pledged Shares | % of Holding | As of |
|---|---|---|---|
| Dhanuka Laboratories Limited | 0 | 0% | 2026-03-31 |
| Quant Mutual Fund - Quant Small Cap Fund | 0 | 0% | 2026-03-31 |
| Kotak Mahindra Trustee Co Ltd A/c Kotak Multi Asset Allocation Fund And 5 Others | 0 | 0% | 2026-03-31 |
| Uti-healthcare Fund And 3 Others | 0 | 0% | 2026-03-31 |
| Invesco India Equity Savings Fund And 2 Others | 0 | 0% | 2026-03-31 |
| Bandhan Bse Healthcare Index Fund And 3 Others | 0 | 0% | 2026-03-31 |
| Dhanuka Laboratories Limited | 0 | 0% | 2025-12-31 |
| Uti Small Cap Fund And 3 Others Under Same Pan | 0 | 0% | 2025-12-31 |
| Invesco India Equity Savings Fund And 4 Others Under Same Pan | 0 | 0% | 2025-12-31 |
| Kotak Mahindra Trustee Co Ltd A/c Kotak Multicap Fund And 5 Others Under Same Pan | 0 | 0% | 2025-12-31 |
| Quant Mutual Fund - Quant Small Cap Fund | 0 | 0% | 2025-12-31 |
| Dhanuka Laboratories Limited | 0 | 0% | 2025-09-30 |
Board of Directors
| Name | Designation | Year |
|---|---|---|
| R G Agarwal | Chairman(Non Exe)&Dir(Non-Ind) | 2025 |
| Manish Dhanuka | Executive Director & MD | 2025 |
| Mridul Dhanuka | E D & Wholetime Director | 2025 |
| Arjun Dhanuka | Non-Exec & Non-Independent Dir | 2025 |
| Dharam Vir | Independent Non Exe. Director | 2025 |
| Manoj Goyal | Independent Non Exe. Director | 2025 |
| Tanu Singla | Independent Non Exe. Director | 2025 |
| Shubha Singh | Independent Non Exe. Director | 2025 |
| Kapil Dayya | Company Sec. & Compli. Officer | 2025 |
Segments — Product
| Segment | Revenue | Share |
|---|---|---|
| Pharmaceuticals | ₹0 Cr | — |
Segments — Geography
| Region | Revenue | Share |
|---|---|---|
| India | ₹181 Cr | 19.9% |
| Rest of the world | ₹728 Cr | 80.1% |
Capital Structure (₹ Cr)
| Year | Face Value | Authorised | Issued | Paid-up |
|---|---|---|---|---|
| 2025 | ₹10 | 150 | 51 | 51 |
Related-Party Transactions (₹ Cr)
| Year | Subsidiaries | Associates | JV | KMP | Others | Total |
|---|---|---|---|---|---|---|
| 2025 | 558 | 0 | 0 | 8 | 233 | — |
| 2025 | 566 | 0 | 0 | 0 | 0 | 566 |
| 2025 | -13 | 0 | 0 | 0 | 0 | -13 |
Insider / Designated-Person Trades
3 recent disclosure(s)
DHANUKA LABORATORIES LIMITEDDisposal · 13,00,000
Dhanuka Laboratories LimitedRevoke · 80,00,015
Dhanuka Laboratories LimitedRevoke · 1,20,00,022
Substantial Acquisitions (SAST)
6 disclosure(s)
Market26/12/2023 · 15,385
Market22/12/2023 · 69,782
Invocation19/12/2023 · 85,167
Market11/12/2023 - 15/12/2023 · 10,00,000
Off Market28/11/2023 · 13,00,000
Release of Shares19/01/2022 · —
Company Information
🌐 www.orchidpharma.com ↗
📍 Orchid Towers Nungambakkam, 313 Valluvar Kottam High Road, Chennai, Tamil Nadu, 600034
Technical AnalysisPremium
Technical analysis (Premium)
Log in to see RSI, MACD, moving averages, oscillators and pivot levels for this stock.
More stocks
Prices are delayed/indicative; pros & cons are AI generated. Informational only — not investment advice. ← Back to search